The proliferation and differentiation of hematopoietic progenitor cells into mature blood cells is a tightly regulated process. Erythrocyte, white blood cell (WBC) and platelet counts are used in medicine as diagnostic and prognostic biomarkers. Inter-individual variation in quantitative blood cell traits is heritable and genome-wide association studies (GWAS) have implicated hundreds of loci^[@R1]--[@R3]^. The development of new genotyping arrays that target protein-coding variation offers new opportunities to assess the role of rare (defined here as minor allele frequency (MAF) \<0.1%) and low-frequency (0.1% ≤ MAF \< 1%) coding variants in human complex trait genetics. We genotyped 6,796 participants from the Montreal Heart Institute (MHI) Biobank and 18,018 women from the Women's Health Initiative (WHI) on the Illumina HumanExome Beadchip, and analyzed associations between 183,585 polymorphic variants and four blood cell phenotypes: hemoglobin, hematocrit, WBC and platelet counts. We carried forward variants in 19 genes (gene-based *P*\<1×10^−4^) and 42 single markers (with *P*\<1×10^−5^ along with *P*\<1×10^−4^ for coding variants in three strong candidate genes: *PKLR*, *BUB1B* and *TUBB1*) for validation of our top association results in 6,526 participants from the Study of Health in Pomerania (SHIP)([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). We identified six genetic associations for platelet count (*TUBB1*, *SH2B3*, *JAK2*), hematocrit/hemoglobin (*EPO, HBB*) and WBC (*CXCR2*) that met our predetermined exome-wide significance threshold (*P*\<6.8×10^−8^ for single variant and *P*\<3.9×10^−7^ for gene-based tests)([Supplementary Fig. 1--3](#SD1){ref-type="supplementary-material"}, [Tables 1](#T1){ref-type="table"}--[2](#T2){ref-type="table"} and [Supplementary Tables 2--4](#SD1){ref-type="supplementary-material"}). These findings highlight the role of rare and low-frequency coding variants in complex traits in large cohorts of apparently hematologically healthy individuals.

We found an association between a low-frequency missense variant (MAF=0.45%) in the erythropoietin gene *EPO* (rs62483572, p.Asp70Asn), that encodes the main cytokine that controls erythrocyte production, and lower hematocrit and hemoglobin levels ([Fig. 1A](#F1){ref-type="fig"} and [Table 1](#T1){ref-type="table"}). Carriers of the *EPO* missense variant had 0.35 g/dl lower hemoglobin and 1% lower hematocrit compared to non-carriers. To our knowledge, the p.Asp70Asn variant is the first naturally-occurring *EPO* coding variant associated with any hematologic phenotype. In the mature EPO protein, p.Asp70Asn (amino acid 43 after cleavage of the signal peptide) is part of the high-affinity receptor binding site ([Supplementary Fig. 4](#SD1){ref-type="supplementary-material"})^[@R4]^. Rare, gain-of-function coding variants of the erythropoietin receptor gene (*EPOR*) have been associated with familial erythrocytosis^[@R5]^. *EPO* is located near transferrin receptor 2 (*TFR2*), a gene important for iron transport and hemoglobin production. Non-coding SNPs in the *TFR2-EPO* region are associated with red blood cell phenotypes^[@R3]^. Conditional analysis on the sentinel SNP *TRF2*-rs7385804 indicated that the rare missense variant in *EPO* is independently associated with hematocrit and hemoglobin ([Fig. 1A](#F1){ref-type="fig"}). This conditional analysis also identified a low-frequency 5' donor splice site variant of *TFR2* (rs139178017) independently associated with higher hematocrit and hemoglobin ([Fig. 1A](#F1){ref-type="fig"} and [Supplementary Table 2](#SD1){ref-type="supplementary-material"}). Other *TRF2* splice site variants have been reported in patients with atypical (*HFE* mutation negative) hemochromatosis^[@R6],[@R7]^.

A rare 5' donor splice site variant in the β-*globin* gene (*HBB*, rs33971440, MAF=0.02%) was associated with lower hemoglobin and hematocrit levels ([Table 1](#T1){ref-type="table"} and [Supplementary Table 2](#SD1){ref-type="supplementary-material"}). This rare *HBB* variant was previously identified in Mediterranean patients with β°-thalassemia^[@R8]^, which may explain why it is present in North American cohorts (MHI and WHI) due to immigration, but absent from Northern Germany SHIP.

Using criteria from the World Health Organization to define anemia (hemoglobin \<12 g/dl in women and \<13 g/dl in men), we confirmed that the *EPO* p.Asp70Asn variant is associated with clinical anemia in the combined analysis of MHI+WHI (1,866 cases and 22,397 controls, odds ratio=1.7, *P*=0.008). The rare *HBB* splice variant is likewise strongly associated with clinical anemia (odds ratio = 36.1, *P*=1.1×10^−5^).

Mutations in *TUBB1* (which encodes a megakarocyte-specific form of β-tubulin, a microtubule protein involved in pro-platelet production) cause autosomal dominant macrothrombcytopenia in humans (MIM 612901) and Cavalier King Charles Spaniel dogs^[@R9]^. We report a new low-frequency *TUBB1* missense variant (rs41303899, p.Gly109Glu, MAF=0.16%) associated with µ33,000/uL lower mean platelet count ([Table 1](#T1){ref-type="table"}). The rs41303899-platelet count association is independent from a common *TUBB1* missense variant (rs6070697, p.Arg307His, MAF=18%, [Supplementary Table 3](#SD1){ref-type="supplementary-material"}) previously associated with mean platelet volume (for rs41303899, meta-analysis *P*=3.7×10^−5^, meta-analysis conditional on rs6070697 *P*=2.4×10^−4^).

*JAK2* p.Val617Phe is the main cause of myeloproliferative neoplasms (MPNs)^[@R10]--[@R13]^. In our discovery sample, *JAK2* p.Val617Phe was strongly associated with platelet count (*P*=3.9×10^−22^), and also with hematocrit (*P*=9.5×10^−7^), hemoglobin (0.002) and WBC count (*P*=3.1×10^−5^), highlighting the pan-lineage effect of this somatic gain-of-function mutation ([Table 1](#T1){ref-type="table"}). *JAK2* p.Val617Phe was rare in MHI and WHI (MAF=0.05%), consistent with prior frequency estimates obtained by whole-exome sequencing^[@R14]^ or allele-specific PCR^[@R15]^ using peripheral blood samples from unselected individuals. The clinical characteristics, serial blood counts and clinical follow-up information obtained for the 19 mutation carriers in the MHI and WHI studies suggest early-stage MPN in these individuals and also exemplify the phenotypic diversity of the *JAK2* p.Val617Phe mutation ([Supplementary Table 5](#SD1){ref-type="supplementary-material"}). Notably, the frequency of the *JAK2* p.Val617Phe mutation appeared to be 10-fold higher in SHIP (MAF=0.4%) ([Table 1](#T1){ref-type="table"}); however, this spuriously high frequency value resulted from genotype mis-calling, as inspection of the genotyping intensity plots does not reveal clearly distinguishable clusters ([Supplementary Fig. 5](#SD1){ref-type="supplementary-material"}). These observations are consistent with both the variable sensitivity to *JAK2* p.Val617Phe detection across genotyping platforms and also heterogeneity of allelic burden across individuals^[@R16],[@R17]^. These issues raise a number of complexities to be considered in the decision to return results of such incidental findings to research participants.

*SH2B3* encodes the adaptor protein LNK, which regulates T and B cell development and myelopoiesis^[@R18]^. LNK inhibits JAK2-STAT and other downstream signaling pathways to modulate hematopoietic cytokine receptor signaling^[@R19]^. Both somatic and germline mutations in *SH2B3* have been reported in patients with MPNs^[@R20],[@R21]^. In addition to confirming the association of a missense SNP (rs3184504, p.Trp262Arg, MAF=50%) with all four hematological traits (*P*\<4.0×10^−10^, [Supplementary Table 3](#SD1){ref-type="supplementary-material"})^[@R1]--[@R3]^, we identified two independent *SH2B3* missense variants associated with higher platelet count (rs148636776, p.Glu395Lys, MAF=0.04%; rs72650673, p.Glu400Lys, MAF=0.1%)([Fig. 1B](#F1){ref-type="fig"}). These two variants are located in the functional SH2 domain that interacts with JAK2 ([Supplementary Fig. 6](#SD1){ref-type="supplementary-material"}). The p.Glu400Lys variant was identified previously in µ5% of patients with idiopathic erythrocytosis^[@R22]^. However, in our dataset there was no association between either p.Glu400Lys or the novel missense variant p.Glu395Lys and hematocritor hemoglobin (*P*\>0.10). *SH2B3* p.Glu395Lys and p.Glu400Lys were not associated with red blood cell (RBC) count in the MHI Biobank (*P*\>0.3). Unfortunately, RBC count is not available in WHI.

In addition to the new associations described above, we confirmed many SNPs previously associated with blood cell traits by GWAS ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}). The only new common variant identified, rs1465788 (MAF=27%), is located in the 5' flanking region of *ZFP36L1* and associates with µ3,000/uL lower mean platelet count ([Table 1](#T1){ref-type="table"}). *ZFP36L1* belongs to a family of mRNA destabilization proteins involved in the regulation of self-renewal and differentiation of hematopoietic cells^[@R23]^. The nearest GWAS index SNP for platelet count is rs11627546, which is located 1.1 megabase away and not in linkage disequilibrium (LD) with rs1465788 (*r*^[@R2]^=0.003 in Europeans)^[@R2]^. Based on ENCODE data from myeloid K562 cells, the rs1465788 variant lies in a nucleosome-depleted region and is in strong LD (*r*^[@R2]^\>0.90 in Europeans) with several common variants in the promoter of *ZFP36L1* ([Supplementary Fig. 7](#SD1){ref-type="supplementary-material"}). Unfortunately, there are no megakaryocyte or platelet expression quantitative trait locus (eQTL) datasets publicly available. Using a large eQTL study of monocytes from 1,490 participants, we were unable to identify eQTL for *ZFP36L1*^[@R24]^. However, according to analyses performed in lymphoblastoid cell lines^[@R25]^, rs1465788 is in LD with rs10873217 (*r*^[@R2]^=0.38 in Europeans), an eQTL for *ZFP36L1*. rs1465788 is also located 77 kilobases downstream of *ACTN1*, a gene mutated in macrothrombocytopenia (MIM 615193), but is neither in LD with markers near *ACTN1* nor an eQTL for *ACTN1* expression. rs1465788, or markers in LD, have been associated by GWAS with autoimmune disorders^[@R26]--[@R28]^. Therefore, it is also plausible that the reason for lower platelet count may involve platelet autoantibody formation, which is a common mechanism of thrombocytopenia in adults^[@R29]^. Several additional common, low-frequency or rare coding variants did not reach our stringent statistical threshold ([Supplementary Tables 2--3](#SD1){ref-type="supplementary-material"}) but are located in strong candidate genes, have been associated with other hematologic traits, or are in LD with a sentinel SNP and could thus explain a GWAS signal. These findings are detailed further in the [Supplementary Note](#SD1){ref-type="supplementary-material"}.

The rare and low-frequency coding variant associations described above represent examples where a single rare variant of large effect dominates the phenotypic association. We report an instance of a novel signal for WBC count in a gene previously undetected through GWAS, where the association is comprised of multiple rare and low-frequency missense variants in *CXCR2* (combined gene-based *P*=2.6×10^−13^, [Table 2](#T2){ref-type="table"} and [Supplementary Table 4](#SD1){ref-type="supplementary-material"}). The gene-based signal is driven mainly by three independent low-frequency *CXCR2* missense variants (rs55799208, p.Arg153His; rs10201766, p.Arg236Cys; rs61733609, p.Arg248Gln) each associated with lower WBC count ([Fig. 2](#F2){ref-type="fig"} and [Supplementary Table 6](#SD1){ref-type="supplementary-material"}; conditional analysis in [Table 2](#T2){ref-type="table"}). The p.Arg153His, p.Arg236Cys, and p.Arg248Gln mutations are located within the second and third intracellular loops of CXCR2, which are important for G-protein interactions and receptor activation ([Supplementary Fig. 8](#SD1){ref-type="supplementary-material"})^[@R30]--[@R32]^. Moreover, the Ala249 residue adjacent to p.Arg248Gln is important for CXCR2 intracellular signaling and also represents an allosteric binding site for CXCR2 antagonists currently undergoing clinical trials^[@R33]^. Upon binding the chemokine CXCL2, CXCR2 signaling promotes neutrophil release from the bone marrow, thereby elevating blood neutrophil counts^[@R34]^. Accordingly, when we analyzed the association between *CXCR2* missense variants and WBC subtypes, the strongest association was with neutrophil count ([Supplementary Table 7](#SD1){ref-type="supplementary-material"}). Common variants of *CXCL2* are associated with WBC, primarily neutrophil count^[@R35]^.

In mice, neutrophils lacking CXCR2 are preferentially retained in the bone marrow^[@R36]^. A congenital neutropenia in humans resembling this condition termed myelokathexis can occur in isolation or as a feature of the rare, autosomal dominant WHIM syndrome^[@R37]^. Most patients with WHIM syndrome have a gain-of-function mutation in the *CXCR4* gene^[@R36],[@R37]^. To further support the role of *CXCR2* mutations in neutropenia and neutrophil trafficking, we studied a pedigree in which two siblings were affected with myelokathexis ([Supplementary Fig. 9](#SD1){ref-type="supplementary-material"}) in the absence of other WHIM syndrome features and in which the involvement of *CXCR4* was excluded^[@R38]^. Sequence analysis of *CXCR2* in affected individuals II-2 and II-4 revealed a homozygous deletion of the coding sequence (c.968delA)([Supplementary Fig. 9](#SD1){ref-type="supplementary-material"}). The encoded mutant protein contains a translational frameshift and premature termination codon after six novel amino acids (H323fs6X, hereinafter referred to as CXCR2fs). We tested the ability of the mutant CXCR2fs receptor to respond to ligand at the level of signal transduction and chemotaxis. Transfected HeLa cells expressing either CXCR2wt or CXCR2fs were stimulated with the ligand CXCL8 over a 15-minute time course. The accumulation of serine-phosphorylated ERK1/2 (pERK) was used to assess the activation of the MAPK signaling cascade. pERK1/2 accumulation was maximal at the five minute timepoint after stimulation of the CXCR2wt receptor, whereas CXCR2fs-transfected cells had no detectable response ([Fig. 3A](#F3){ref-type="fig"}). Consistent with these results, CXCR2wt-transfected cells had a robust chemotactic response to CXCL8, whereas cells expressing CXCR2fs did not, supporting the notion that the frameshift mutation caused a loss of receptor function ([Fig. 3B](#F3){ref-type="fig"}). Together with our population-based results, these family and functional data support the concept that CXCR2 regulates neutrophil mobilization from the bone marrow and peripheral neutrophil counts.

Our results clearly demonstrate that rare and low-frequency coding variants contribute to phenotypic variation in human populations. We discovered novel missense variants in key regulators of hematopoiesis (*EPO*, *SH2B3*, *TUBB1)* that have potential implications for diagnostic screening and drug development in a variety of hematologic and inflammatory disorders (cytopenias, MPNs, lung disease, stroke). For example, rare *SH2B3* mutations may account for additional cases of *JAK2*-negative MPNs. We also provide further support for the biological role of several molecules in the regulation of hematopoiesis (*CXCR2*, *ZFP36L1*). Collectively, our findings validate exome-wide genotyping in very large samples as an effective and complementary tool to GWAS and deep DNA re-sequencing studies for defining the allelic architecture of complex traits. The association between a collection of rare and low-frequency *CXCR2* coding variants and WBC count emphasizes the relevance of gene-based tests as we continue to query even rarer variants for their role in human phenotypic variation.

Methods {#S1}
=======

Study participants and phenotypes {#S2}
---------------------------------

The MHI Biobank is a longitudinal cohort with the aim to recruit 30,000 patients of the MHI for clinical and genetic research^[@R39]^. Participants are recruited from different departments within the MHI and at its affiliated EPIC centre, the largest fitness centre in Canada for coronary patients and research in primary and secondary prevention. The MHI ethics committee approves the project and informed consent is obtained from all participants. The MHI Cohort collects data by using a 35-page questionnaire administered by a research nurse at baseline including demographics, personal and family medical history, physical activity, diet, tobacco, medication use, as well as depression and hostility questionnaires. Vital signs (heart rate, blood pressure, weight, height, waist circumference) are obtained by the nurse and blood, DNA, and plasma are collected and stored at the Beaulieu-Saucier Pharmacogenomics Center. Patients' health status is confirmed by the nurse by using the Hospital's health record for retrospective and prospective follow-up. The Cohort's database is updated frequently with patients' medical information from the hospital's electronic records. A follow-up study questionnaire is administered every four years. Blood cell counts and other related phenotypes were automatically generated with the UniCel DxH 800 cellular analysis system from Beckman Coulter.

The Women's Health Initiative (WHI) is one of the largest (n=161,808) U.S. studies of women's health. This project was approved by the ethics committee at the Fred Hutchinson Cancer Research Center. The WHI consists of two main components: (1) a clinical trial that enrolled 68,132 post-menopausal women ages 50--79 and randomized them to one of three placebo-controlled clinical trials of hormone therapy, dietary modification, or supplementation with calcium and vitamin D; and (2) an observational study that enrolled 93,676 women of the same age range into a parallel prospective study.^[@R40]^ Of the women in WHI who were eligible and consented to genetic research, 18,072 were included in the current study. Samples for blood count were collected at baseline by venipuncture into tubes containing ethylenediaminetetraaetic acid (EDTA). Blood counts were performed with automated hematology cell counters and standardized quality-assurance procedures. Hemoglobin, hematocrit, WBC, and platelet count were the only complete blood count values recorded at data entry during the WHI baseline examination, which was conducted nationwide during 1993--1998.

The Study of Health in Pomerania consists of two independent prospectively collected population-based cohorts in West Pomerania (SHIP and SHIP-TREND), a region in the northeast of Germany, assessing the prevalence and incidence of common population-based diseases and their risk factors. The study followed the recommendations of the Declaration of Helsinki. The study protocol of SHIP was approved by the medical ethics committee of the University of Greifswald. Written informed consent was obtained from each of the study participants. The study design has been previously described in details^[@R41]^. Briefly, a sample from the population aged 20 to 79 years was drawn from population registries. First, the three cities of the region (with 17,076 to 65,977 inhabitants) and the 12 towns (with 1,516 to 3,044 inhabitants) were selected, and then 17 out of 97 smaller towns (with less than 1,500 inhabitants), were drawn at random. Second, from each of the selected communities, subjects were drawn at random, proportional to the population size of each community and stratified by age and gender. Only individuals with German citizenship and main residency in the study area were included.

For SHIP, baseline examinations were carried out from 1997 until 2001, and the sample finally comprised 4,308 participants. Baseline examinations for SHIP-TREND were carried out between 2008 and 2012, finally comprising 4420 participants. The blood count was measured within 60 minutes. The samples were analyzed at the hospital laboratory in Greifswald with a Coulter Max M analyzer (Coulter Electronics, Miami, USA) and with a Coulter T660 analyzer (Coulter Electronics, Miami, USA) at the hospital laboratory in Stralsund. Both analyzers were calibrated and maintained according to the manufacturers' instructions. Quality control was performed internally as well as externally by participating in external proficiency testing programs. For this project, data of SHIP-TREND and the first 5-year follow-up of SHIP were included. In all association analyses, the cohort was included as an additional covariate in the model.

Genotyping and quality-control steps {#S3}
------------------------------------

We attempted to genotype 10,856 participants from the MHI Biobank on the Illumina ExomeChip array (version Infinium HumanExome v1.0 DNA Analysis BeadChip). Genotyping was performed at the MHI Pharmacogenomics Centre. We initially called genotypes with Illumina's GenomeStudio software and, after data quality control (see below), recalled missing genotypes with the zCall software^[@R42]^. We carried out most quality control steps in PLINK^[@R43]^, and developed additional custom scripts when needed. We excluded markers with genotyping success rate \<95% and Hardy-Weinberg equilibrium *P*\<1×10^−4^. We excluded samples with genotyping success rate \<95%%, abnormal heterozygosity (inbreeding F values \<-0.2 or \>0.1) and extensive low-level identity-by-descent (IBD) sharing with a large number of samples. Genotype concordance calculated from samples genotyped in duplicate or samples also sequenced by the 1000 Genomes Project^[@R44]^ was \>99.99%. To identify population outliers, we used principal component analysis as implemented in EIGENSOFT^[@R45]^ and anchor our analysis on continental populations from the 1000 Genomes Project^[@R44]^. For this study, we only analyzed individuals of European ancestry. We used the GCTA software^[@R46]^ to detect cryptic relatedness: we removed one individual from each pair of samples that share \>18% of their genome (corresponding to duplicates and first- and second-degree relatives). Our final dataset includes 9,656 individuals and 136,997 polymorphic markers. Blood cell phenotypes are available for 6,796 MHI Biobank participants ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}).

DNA samples from the WHI clinical coordinating center were sent to the Broad Institute (BI) or the Translational Genomics Research Institute (TGEN) for genotyping and were placed on 96-well plates for processing using the Illumina HumanExome v1.0 SNP array. Genotypes were assigned using GenomeStudio v2010.3. All genotypes were then merged into a master-file containing all genotypes from the BI and TGEN. Quality control was performed on this master-file using the PLINK and R^[@R47]^ computing platforms. We excluded markers with a genotyping success rate less than 99%. We excluded samples with a genotyping success rate less than 98%. With the resulting sample set, we performed a principal component (PC) analysis as well as an analysis of relatedness using the PLINK IBS/IBD functionality. Outlier samples on the PC plots were excluded as were samples that were determined to be contaminated via the relatedness analysis (i.e., they were apparently related to hundreds of other samples). For each related/duplicate pair of samples, we excluded the sample with the lower call-rate. Unexpected duplicate samples were also filtered to prevent potential samples swaps from entering the analysis. For intentionally duplicated samples, we removed samples with low relatedness estimates as we expect them to be close to 1. We excluded samples with hemoglobin levels greater than 20 g/dl or a hematocrit (%) to hemoglobin (g/dl) ratio greater than 5. Samples with WBC (x10^9^/l) greater than 100 were also excluded from the analysis. After QC, there were 18,072 samples and 166,836 polymorphic markers.

The SHIP and SHIP-TREND samples were genotyped using the Illumina ExomeChip array (version Infinium HumanExome v1.0 DNA Analysis BeadChip). Hybridisation of genomic DNA was done in accordance with the manufacturer's standard recommendations at the Helmholtz Zentrum München. Genotype calling was performed according to the ExomeChip quality control SOP version 5. Initial genotypes were determined using the GenomeStudio Genotyping Module v1.0 (GenCall algorithm) with the HumanExome-12v1_A manifest file and the standard Illumina cluster file (HumanExome-12v1.egt). Contaminated samples, samples with a call rate \<90%, extreme heterozygosity, extensive estimated IBD sharing with a large number of samples, or mismatch between reported and genotyped gender were excluded. Next, missing genotypes were re-called with the zCall software version 3.3 using the default values. In both cohorts together, 7366 individuals were successfully genotyped with an average call rate of 99.97%.

Trait modeling and study-level association testing {#S4}
--------------------------------------------------

We used untransformed HGB, HCT and PLT values and log10-transformed WBC values for association testing. Because the analysis of rare variants is particularly sensitive to phenotypic outliers, we winsorized our data such that all individuals with a phenotype below the 0.5% or above the 99.5% of the trait distribution were respectively assigned the phenotype corresponding to 0.5% and 99.5% values. In our analysis, phenotype winsorisation reduced inflation while maintaining phenotype scale. In MHI, we used sex, age, age-squared and the first ten principal components as covariates. In WHI, we used age, and the first two principal components as covariates. We also included a term in the linear model to account for the different WHI sub-studies that contributed to this project.

We used PLINK^[@R43]^ to test association between phenotypes and single variant genotypes (including single variant conditional analyses) under an additive genetic model. For the gene-based analyses, each cohort ran an analysis with the rvtests software^[@R48]^. This software calculates a score statistic for each variant and a covariance matrix for markers within sliding windows.

Meta-analysis and statistical significance {#S5}
------------------------------------------

We combined single variant results with metal using the inverse variance method^[@R49]^. For the gene-based tests, we combined score test results from rvtests with the raremetal software using default parameters^[@R48]^. *A priori*, we decided to focus exclusively on missense and nonsense variants as well as variants within donor or acceptor splice sites for these analyses. For each trait, we ran two gene-based test: a simple burden test with a minor allele frequency (MAF) cutoff of \<1% (burden T1) and the sequence kernel association test (SKAT) with a MAF cutoff of \<5%.

We defined statistical significance using Bonferroni corrections. For single variant analyses, we tested 183,585 DNA sequence variants and four phenotypes: α = 0.05 / 183,585 variants / 4 phenotypes = 6.8×10^−8^. For gene-based analyses, we tested 15,930 genes (genes with no or only one missense/nonsense/splice site variants were not tested), four phenotypes and two different statistical tests: α = 0.05 / 15,930 genes / 4 phenotypes / 2 tests = 3.9×10^−7^.

Functional characterization of CXCR2 {#S6}
------------------------------------

A previously described family in which two sisters were affected with isolated myelokathexis^[@R14]^ was evaluated for mutations in *CXCR2*. The clinical manifestations in this family included neutropenia without lymphopenia or warts leading to recurrent bacterial infections including septic thrombophlebitis and subacute bacterial endocarditis. At age 43, one of the siblings was reported to have had \>80 infectious episodes^[@R31]^. Her younger sister had fewer infectious episodes, which was speculated to result from a more robust transient release of neutrophils into the peripheral blood during infection. The family was lost to follow up and not available for further functional studies on primary cells.

Human CXCR2 is encoded by a single exon with multiple upstream non-coding exons giving rise to a number of different splice isoforms. The coding sequence of the gene was amplified on three overlapping PCR fragments and analyzed by automated sequencing. Exonic boundaries were identified using publicly available genomic database information^[@R50]^ and primers were designed to amplify coding exons and flanking intronic sequences using the Primer3 software^[@R51]^. PCR amplicons were sequenced using an ABI3700 automated platform. Confirmatory restriction enzyme analysis was performed using *Nco*I (New England Biolabs) under standard conditions.

IMAGE clone 5752441 containing the full-length CXCR2 open reading frame was obtained from Invitrogen. The insert was confirmed by sequencing the clone using CXCR2-specific primers. The 968delA (CXCR2fs), C967T/T969G (H323X), and 968delA/986insC (CXCR2fs-wt) mutations were introduced by site-directed mutagenesis primers and amplified by *Pfu*Turbo (Stratagene). The resulting clones were tagged with epitopes on the C-terminal tail of the receptor by PCR amplification of the CXCR2 open reading frame using the IMAGE clone as a template. The amplification primers contained exogenous restriction sites at the 3' and 5' ends and were digested using *Eco*RI/*Xho*I (FLAG) or *Eco*RI/*Sal*I (YFP). After digestion with the appropriate enzymes, fragments were ligated in-frame upstream of the 3xFLAG epitope in pIRES-3xFLAG-hrGFP (Invitrogen) or the YFP full-length protein in pEYFP-N1 (Clontech). The full-length ORFs for FLAG-tagged and YFP-fusion proteins were sequence verified.

HEK293 and HeLa cell cultures were maintained in 5% CO~2~ at 37°C in DMEM (Cellgro) supplemented with 10% fetal bovine serum (Gibco), 2mM L-glutamine, 100 U/mL penicillin and 100 µg/mL streptomycin (Cellgro). Cultures were transfected using FuGENE-6 (Roche) according to the manufacturer's protocol. Transgene expression was evaluated 36--72 hrs post-transfection by indirect immunofluorescence or western blot. Primary antibodies used in these studies - anti-FLAG (Sigma), anti-CXCR2 (Santa Cruz Biotechnology), anti-GFP (Molecular Probes), anti-calnexin (Chemicon), anti-phospho-ERK/-ERK (Santa Cruz Biotechnology) - were used at dilutions as suggested by manufacturer. Anti-rabbit and anti-mouse HRP conjugates (Pierce) were used as secondary antibodies for Western blots and FITC-labeled anti-mouse (SCBT), rabbit-AF594- and AF488-labeled anti-rabbit (Invitrogen) and direct-labeled Phalloidin-AF594 (Molecular Probes) were used for immunofluorescence microscopy. Fluorescein-labeled monoclonal 48311 anti-CXCR2 (R&D Systems) and phycoerythrin-labeled 12G5 monoclonal anti-CXCR4 (Pharmingen) and labeled isotype control antibodies were used for flow cytometry experiments.

Transfected HeLa cells were made quiescent in serum-free, antibiotic-free DMEM overnight prior to the addition of ligand. Cells (1 × 10^6^) were stimulated with 100 ng/mL CXCL8, 100 ng/mL CXCL12 (Cell Sciences) or kept in serum-free medium for times as described in figure legends. Cells were either harvested for Western analysis or fixed for immunofluorescence staining.

Prior to harvesting, cells were rinsed with ice cold PBS, lysed on ice in RIPA lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1.0% Triton X-100, 0.5% DOC, 0.1% SDS, 0.025% NaN~3~) supplemented with Complete protease inhibitor cocktail (Roche) for a minimum of 30 minutes. After determination of protein concentration by Bradford assay, lysates were denatured in 1x Laemmli sample buffer with 100 mM DTT and equivalent amounts run on 10% SDS-PAGE gels. Proteins were transferred to nitrocellulose (Pall/GE) using the Bio-Rad Semi-Dry Trans-Blot system for 1 hour, blocked in 5% milk in PBS (w/v) for 1 hour, then incubated overnight at 4°C in primary antibody. Blots were washed three times for 10 minutes in PBS-Tween-20 (0.05%). Incubation with species-specific HRP-conjugated antibody for 1 hour was followed by three more 10 min washes in PBST. Membranes were developed using SuperSignal West Pico and Chemiluminescent Substrate (Pierce) on HyBlot CL Film (Denville). For deglycosylation experiments, 30 µg of total protein was incubated with Endo Hf (NEB), PNGase F (NEB) or buffer alone for 1 hour at 37°C as recommended by manufacturer.

Cells were transfected with CXCR2 constructs as described below and an aliquot of cells resuspended by trypsin treatment were fixed for 15 minutes using 2.2% paraformaldehyde (Electron Microscopy Sciences) in PBS (v/v) then spun down at 500*g* for 5 minutes. Cells were washed twice in Flow Buffer (PBS with 0.5% BSA (w/v), 5 mM EDTA) to inhibit clumping of cells. Approximately 2.5 × 10^5^ cells in 50 µl aliquots were used for each assay. Flow cytometric data for quantitation of CXCR2 construct expression were collected using a FACS LSR II (Becton Dickson). All data were analyzed using Flowjo software (Tree Star, Inc, Ashland, OR 97520). At least three independent experiments were performed for each condition tested.

HeLa cells at 70% confluence in 10 cm dishes were transfected with either pEYFP-N1-CXCR2wt or pEYFP-N1-CXCR2wt and cultured for 3 days. After overnight serum-starvation, cells were harvested on the fourth day and resuspended in DMEM/0.5% BSA at a density of 5×10^5^ cells/100 µl. 100 µl aliquots were added to the upper chamber of 24-well Transwell plates (Corning-Costar) with collagen-coated 8.0 µm pore polycarbonate membranes. Chemotaxis was assayed by addition of CXCL8 (100ng/ml) to DMEM in the bottom chamber of the plates. After 2 hours in a 37° C, 5% CO~2~ tissue culture incubator, inserts were removed, loose cells scraped off and transmigrated cells fixed and stained in Crystal Violet. Cells migrated onto the lower surface of the membrane were counted for five low power (10X) fields using a brightfield inverted microscope to determine the average cell number migrated per field. Chemotactic index was calculated by dividing the average number of cells migrated per field under conditions of chemokine addition by the average number under conditions of saline addition. Experiments were performed in triplicate at least three times each.
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![Association results in the meta-analysis MHI+WHI (N=24,814) for (A) hematocrit at the *TFR2-EPO* locus on chromosome 7 and (B) platelet count at the *SH2B3* locus on chromosome 12. The *x*-axis corresponds to genomic coordinates. (A) For *TFR2-EPO*, we provide association results for each variant in the region before (circles) and after (stars) conditioning on the GWAS sentinel SNP at the locus (rs7385804). (B) Similarly, for *SH2B3* we provide association results without (circles) and with (stars) adjustment for genotypes at the GWAS sentinel SNP rs3184504. In the GWAS row, we represent all markers in linkage disequilibrium (LD) with the GWAS sentinel SNP (marked by an inverted triangle) based on data from European populations in the 1000 Genomes Project: the size of the circle is proportional to the strength of LD. We added a vertical line between the GWAS and ExomeChip rows if GWAS LD proxies were also present on the ExomeChip array. On the ExomeChip row, all markers analyzed in the region are represented as triangles (intronic, intergenic and synonymous variants) or diamonds (missense, nonsense and splice site variants). Vertical lines between the ExomeChip and Freq 0.5 rows represent allele frequencies in the meta-analysis MHI+WHI.](nihms581495f1){#F1}

![Rare and low-frequency missense variants in *CXCR2* are associated with lower white blood cell (WBC) count. The symbol legend is in the upper left corner of the figure. A vertical line represents the mean WBC count for each study. The middle of each color-coded circle (black=MHI, white=WHI, grey=SHIP) corresponds to the mean WBC count for individuals that carry the corresponding missense variants and the size of the circles is correlated with allele frequency. The three white circles in the lower left corner of the figure are provided as references and represent variants with minor allele frequency of 0.01%, 0.1% and 0.5%. For rs2228413 (p.Arg294Gln), there is a participant from MHI that is homozygote for the rare allele (star).](nihms581495f2){#F2}

![Functional characterization of the CXCR2fs mutant receptor. (A) Intracellular ERK1/2 signaling in HeLa cells transfected with wild type or mutant CXCR2 receptor. HeLa cells transfected with CXCR2wt-YFP, CXCR2fs-YFP or YFP alone were stimulated with CXCL8 (100 ng/mL) and lysates collected over the time course indicated to assess the activation of the ERK1/2 pathway. Peak phosphorylation following stimulation of CXCR2wt occurred at 5 min with significant attenuation of activation by 15 min. No activation over baseline was detected in cells expressing CXCR2fs. ERK1/2 activation at 5 min following stimulation of endogenous CXCR4 with CXCL12 (100 ng/mL) was used as a positive control (+). Protein abundance of CXCR2wt-YFP (wt), CXCR2fs-YFP (fs) and the YPF control (Y) proteins in transfected cell lines are shown (right panel). (B) Chemotaxis assay results for HeLa cells expressing CXCR2wt-YFP or CXCR2fs-YFP. Transiently transfected HeLa cells were seeded in the top chamber of modified Boyden chambers and CXCL8 (100 ng/mL) was added to media in the bottom chamber. The chemotactic index (migration in presence of CXCL8/migration in absence of CXCL8) was calculated from the results of assays performed in triplicate. Robust migration was observed in cells expressing the wild type CXCR2 fusion protein (gray bars), but not in those expressing the frameshift mutant (open bars) or in untransfected cells (black bars). Overexpression of each construct was confirmed by detecting YFP fluorescence (expressed as relative fluorescence units; RFU) in aliquots of transfectants (right panel). \**P*\<0.02, Student's *t*-test, n.s., non-significant.](nihms581495f3){#F3}

###### New genome-wide significant variants associated with blood cell traits

Variants that reach a *P*\<6.8×10^−8^ in the combined analysis and are either outside the GWAS loci or independent of the GWAS sentinel SNPs for hematological traits. Sample size: Discovery MHI+WHI (N=24,814); Replication SHIP (N=6,526); Combined (N=31340). The direction of the effect sizes (Beta) is for the A1 allele. Effect sizes and standard errors (SE) are in the following units: for hematocrit (%), for hemoglobin (g/dl) and for platelet (x10^9^/l). n.d.; not determined because the marker is monomorphic in SHIP. Genomic positions are on the human genome build hg19. bp; base pair. n.a.; not applicable.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variant            Chr (Pos)       A1/A2           Stage         Freq (A1)     Beta (SE)        *P*           Hetero*P*   Gene      Annotation
  ------------------ --------------- --------------- ------------- ------------- ---------------- ------------- ----------- --------- ------------------------
  ***HEMATOCRIT***                                                                                                                    

  rs62483572         7:100,319,633   A/G             Discovery     0.0045        −1.07 (0.21)     3.5×10^−7^    n.a.        *EPO*     Missense\
                                                                                                                                      (p.Asp70Asn)

  Replication        0.0041          −1.11 (0.40)    0.0053        n.a.                                                               

  Combined           n.a.            −1.08 (0.19)    6.4×10^−9^    0.94                                                               

  ***HEMOGLOBIN***                                                                                                                    

  rs62483572         7:100,319,633   A/G             Discovery     0.0045        −0.35 (0.07)     9.5×10^−7^    n.a.        *EPO*     Missense\
                                                                                                                                      (p.Asp70Asn)

  Replication        0.0041          −0.35 (0.14)    0.011         n.a.                                                               

  Combined           n.a.            −0.35 (0.06)    3.4×10^−8^    0.96                                                               

  rs33971440         11:5,248,159    T/C             Discovery     0.0002        −2.41 (0.44)     3.7×10^−8^    n.a.        *HBB*     5\' donor splice\
                                                                                                                                      site(exon2:c.92+1G\>A)

  Replication        Monomorphic     n.a.                                                                                             

  Combined           n.d.                                                                                                             

  ***PLATELETS***                                                                                                                     

  rs77375493         9:5,073,770     T/G             Discovery     0.0005        124.09 (12.83)   3.9×10^−22^   n.a.        *JAK2*    Missense\
                                                                                                                                      (p.Val617Phe)

  Replication        0.0041          16.41 (8.61)    0.057         n.a.                                                               

  Combined           n.a.            49.86 (7.15)    3.1×10^−12^   3.2×10^−12^                                                        

  rs1465788          14:69,263,599   T/C             Discovery     0.27          −2.75 (0.58)     2.1×10^−6^    n.a.        n.a.      639 bp upstream of\
                                                                                                                                      *ZFP36L1*

  Replication        0.27            −3.06 (1.01)    0.0024        n.a.                                                               

  Combined           n.a.            −2.82 (0.50)    1.9×10^−8^    0.78                                                               

  rs41303899         20:57,598,808   A/G             Discovery     0.0016        −27.70 (6.72)    3.7×10^−5^    n.a.        *TUBB1*   Missense\
                                                                                                                                      (p.Gly109Glu)

  Replication        0.0024          −42.63 (9.07)   2.7×10^−6^    n.a.                                                               

  Combined           n.a.            −32.99 (5.40)   9.9×10^−10^   0.19                                                               
  ------------------------------------------------------------------------------------------------------------------------------------------------------------

###### Gene-based association results

We list in this table genes that are exome-wide significant (*P*\<3.9×10^−7^) or that have both strong statistical evidence and biological candidacy. The remaining gene-based results are in [Supplementary Table 4](#SD1){ref-type="supplementary-material"}. We analyzed association between rare non-synonymous (missense, nonsense) and splice site variants and blood cell traits using the Burden T1 and SKAT gene-based tests. When applicable, we also conditioned on GWAS sentinel SNPs or excluded low-frequency variants strongly associated with the traits.

                                           MHI+WHI (N=24,814)   SHIP (N=6,526)   Combined (N=31,340)                                       
  ------------------ ----------- --------- -------------------- ---------------- --------------------- ------------ ---- ------------ ---- -------------
  Hematocrit         SKAT        *EPO*     5                    4.6×10^−5^       1.0×10^−4^            0.13         4    0.033        5    1.4×10^−6^
  Hemoglobin         Burden T1   *HBB*     4                    9.2×10^−5^       n.a.                  0.031        2    0.23         5    4.3×10^−5^
  Hemoglobin         SKAT        *EPO*     5                    7.8×10^−5^       9.6×10^−5^            0.16         4    0.072        5    4.0×10^−6^
  White blood cell   Burden T1   *CXCR2*   8                    1.6×10^−6^       n.a.                  8.2×10^−4^   6    8.3×10^−9^   8    2.6×10^−13^
  Platelet           SKAT        *SH2B3*   14                   2.2×10^−7^       3.9×10^−8^            0.078        11   0.024        16   8.3×10^−7^
  Platelet           SKAT        *TUBB1*   13                   2.2×10^−5^       3.1×10^−5^            0.018        8    2.9×10^−4^   14   6.7×10^−10^

For *EPO, SH2B3*, and *TUBB1*, we conditioned respectively on rs7385804, rs3184504, and rs6070697.

For *EPO*, we excluded rs62483572, for *HBB*, we excluded rs33971440, for *CXCR2*, we excluded rs61733609, for *SH2B3*, we excluded rs72650673, and for *TUBB1*, we excluded rs41303899. n.a.; not applicable.

[^1]: These authors co-directed the study.
